Sukumar Nagendran

Director, President and Head of R&D · 1 filing · Latest: Apr 10, 2026

Taysha Gene Therapies, Inc.

Ticker	Owner	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TSHA	Sukumar Nagendran	Director, President and Head of R&D	Apr 10, 2026	Sale	$4.46	200,000	$892.0K	1,136,410	Apr 13 4:33 PM
TSHA	Sukumar Nagendran	Director, President and Head of R&D	Apr 10, 2026	Option Exercise	$1.71	19,021	$32.5K	1,336,410	Apr 13 4:33 PM